-
MIRA Pharmaceuticals' Marijuana Analog Mira-55 Shows Potent Pain Relief In Preclinical Study, Stock Jumps 50% After Hours
Thursday, July 3, 2025 - 1:46am | 630Read More...MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) shares soared to $1.87, an approximate 50.8% jump, during after-hours trading on Wednesday. What Happened: After the announcement of Mira-55, a synthetic analog of marijuana, providing pain relief comparable to morphine, the stock value of MIRA...
-
Cannabis Terpenes Alleviate Chemo-Induced Neuropathic Pain, Study Shows Added Benefits With Morphine And Reduced Addiction Risk
Wednesday, May 29, 2024 - 9:36am | 555Read More...A recent University of Arizona Health Sciences study has found that terpenes from Cannabis sativa are as effective as morphine in reducing chronic neuropathic pain, with the added benefit of enhancing pain relief when used together with morphine and without negative side effects. Historically, the...
-
AcelRx CFO Shares Update On DoD Relationship And More After FDA Accepted NDA For DSUVIA
Tuesday, February 28, 2017 - 6:45pm | 774Read More...Micro-cap specialty pharmaceutical company AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) announced Monday the FDA accepted its New Drug Application for DSUVIA, its treatment for moderate-to-severe acute pain in medically supervised settings. In addition, the federal agency set a PDUFA date of Oct. 12,...
